The impact of legislation on drug substances used off-label in paediatric wards - A nationwide study

European Journal of Clinical Pharmacology

Volumn 70, Issue 4, 2014, Pages 445-452

  Haslund Krog, Sissel ^a   Mathiasen, René ^b   Christensen, Hanne Rolighed ^a   Holst, Helle ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Children; Off label; Paediatric investigation plan; Paediatric regulation; Standard assortments

Indexed keywords

AMPHOTERICIN B; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; COLCHICINE; CONTRACEPTIVE AGENT; CORTICOSTEROID; CYCLOSPORIN A; ESOMEPRAZOLE; ESTRADIOL; GOLIMUMAB; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCORTISONE; INFLIXIMAB; LEUPRORELIN; MACROLIDE; MELATONIN; MEROPENEM; METHYLPREDNISOLONE; METOPIMAZINE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PHENYLEPHRINE; POSACONAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TESTOSTERONE; TINZAPARIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; DENMARK; HEALTH CARE NEED; HUMAN; INVASIVE ASPERGILLOSIS; JUVENILE RHEUMATOID ARTHRITIS; LAW; NEWBORN; OFF LABEL DRUG USE; PREMATURITY; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; REFERENCE DATABASE; SCHOOL CHILD; ULCERATIVE COLITIS; YOUNG ADULT; DRUG APPROVAL; DRUG LABELING; DRUG UTILIZATION; EUROPE; INFANT; LEGISLATION AND JURISPRUDENCE; PEDIATRICS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG APPROVAL; DRUG LABELING; DRUG UTILIZATION; EUROPE; HUMANS; INFANT; INFANT, NEWBORN; OFF-LABEL USE; PEDIATRICS;

EID: 84896489191     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1626-1     Document Type: Article

References (36)

1. Kimland E, Nydert P, Odlind Vet al (2012) Paediatric drug use with focus on off-label prescriptions at Swedish hospitals - a nationwide study. Acta Paediatr 101:772-778. doi:10.1111/j.1651-2227.2012.02656.x
2. Cuzzolin L, Atzei A, Fanos V (2006) Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf 5:703-718. doi:10.1517/14740338.5.5.703 (Pubitemid 44322888)
3. 't Jong GW, van der Linden PD, Bakker EM et al (2002) Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol 58:293 - 297. doi:10.1007/s00228-002-0479-9
4. Lindell-Osuagwu L, KorhonenMJ, Saano S et al (2009) Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 34:277-287
5. Conroy S, Choonara I, Impicciatore P et al (2000) Survey of unlicensed and off-label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 320:79-82 (Pubitemid 30173044)
6. Cohen E, Uleryk E, Jasuja M, Parkin PC (2007) An absence of pediatric randomized controlled trials in general medical journals, 1985-2004. J Clin Epidemiol 60:118-123. doi:10.1016/j.jclinepi.2006.03.015 (Pubitemid 46039874)
7. EMA document (2006) Official Journal of the European Union. Paediatric Regulation (EC) No 1901/2006. http://ec.europa.eu/health/files/eudralex/vol-1/ reg-2006-1901/reg-2006-1901-en.pdf. Accessed 4 Mar 2013
8. Olski TM, Lampus SF, Gherarducci G, Saint Raymond A (2011) Three years of paediatric regulation in the European Union. Eur J Clin Pharmacol 67:245 - 252. doi:10.1007/s00228-011-0997-4
9. Knellwolf A-L, Bauzon S, Alberighi ODC et al (2011) Framework conditions facilitating paediatric clinical research. Ital J Pediatr 37:12. doi:10.1186/1824-7288-37-12
10. EMA document (2010) Report on the survey of all paediatric uses of medicinal products in Europe. http://www.ema.europa.eu/ema/index.jsp?curl=pages/ regulation/document-listing/document-listing-000096.jsp. Accessed 9 Sep 2013
11. Data base (2012) BIWeb. http://bihost.dk/amgros/login.aspx?ReturnUrl= %2famgros%2fdefault.aspx. Accessed 20 Nov 2012
12. WHOCC - ATC/DDD Index. http://www.whocc.no/atc-ddd-index/. Accessed 8 Mar 2013
13. EMAWebsite (2012) EuropeanMedicines Agency - Find medicine - European public assessment reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/landing/epar-search.jsp&mid=WC0b01ac058001d124. Accessed 8 Mar 2013
14. Danish Health and Medicine Authority (2012) Summary of product characteristics. http://www.produktresume.dk/docushare/dsweb/View/Collection-96. Accessed Dec 2012
15. Kimland E, Odlind V (2012) Off-label drug use in pediatric patients. Clin Pharmacol Ther 91:796-801. doi:10.1038/clpt.2012.26
16. WHO document (2013) WHOCC - Use of ATC/DDD. http://www.whocc.no/use-of- atc-ddd/. Accessed 22 Feb 2013
17. European Commission document (2013) Better medicines for children from concept to reality. http://ec.europa.eu/health/files/paediatrics/2013-com443/ paediatric-report-com(2013)443-en.pdf. Accessed 14 Oct 2013
18. Teutonico D, Montanari S, Ponchel G (2012) Leuprolide acetate: pharmaceutical use and delivery potentials. Expert Opin Drug Deliv 9:343-354. doi:10.1517/17425247.2012.662484
19. Fuqua JS (2013) Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab 98:2198-2207. doi:10.1210/jc.2013-1024
20. Dupuis LL, Nathan PC (2010) Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines. Paediatr Drugs 12:51-61. doi:10.2165/11316190-000000000-00000
21. Nathan PC, Tomlinson G, Dupuis LL et al (2006) A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design. Support Care Cancer 14: 268-276. doi:10.1007/s00520-005-0875-7 (Pubitemid 43247931)
22. EuropeanMedicines Agency - EMEA-000265-PIP02-11 - Golimumab. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/pip-search. jsp&mid=WC0b01ac058001d129&source=homeMedSearch&keyword= golimumab&isNewQuery=true. Accessed 15 Oct 2013
23. European Medicines Agency - EMEA-000265-PIP01-08-M02 - Golimumab. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/pip-search. jsp&mid=WC0b01ac058001d129&source=homeMedSearch&keyword= golimumab&isNewQuery=true. Accessed 15 Oct 2013
24. Broe J, Platz MA, Nielsen S et al (2013) Off-label use and adverse events of biologic agents in paediatric patients with juvenile idiopathic arthritis. Clin Ther 35:1-2 suppl
25. Garazzino S, Lutsar I, Bertaina C et al (2013) New antibiotics for paediatric use: a review of a decade of regulatory trials submitted to the European Medicines Agency from 2000-why aren't we doing better? Int J Antimicrob Agents 42:99 - 118. doi:10.1016/j.ijantimicag.2013.05.001
26. Kemper EM, Merkus M, Wierenga PC et al (2011) Towards evidence-based pharmacotherapy in children. Paediatr Anaesth 21: 183-189. doi:10.1111/j.1460- 9592.2010.03493.x
27. Tynjälä P, Lindahl P, Honkanen V et al (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66:548-550. doi:10.1136/ard.2006. 058248 (Pubitemid 46580481)
28. Foeldvari I, Nielsen S, Kümmerle-Deschner J et al (2007) Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 34:1146-1150 (Pubitemid 46774863)
29. EuropeanMedicines Agency with its Paediatric Committee (2012) 5-year Report to the European Commission. http://ec.europa.eu/health/files/paediatrics/ 2012-09-pediatric-report-annex1-2-en.pdf. Accessed 19 Feb 2013
30. EMA document (2013) Successes of the paediatric regulation after 5 years. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/06/ news-detail-001823.jsp&mid=WC0b01ac058004d5c1. Accessed 19 Jun 2013
31. European Medicines Agency - EMEA-000130-PIP01-07 - Paracetamol. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/ EMEA-000130-PIP01-07/pip-000279.jsp&mid=WC0b01ac058001d129. Accessed 2 Oct 2013
32. EMA document Paediatric Medicines Section (2013) Report to the European Commission. http://ec.europa.eu/health/human-use/paediatric-medicines/ developments/. Accessed 2 Oct 2013
33. Allegaert K, Naulaers G, Vanhaesebrouck S, Anderson BJ (2013) The paracetamol concentration-effect relation in neonates. Paediatr Anaesth 23:45-50. doi:10.1111/pan.12076
34. Allegaert K, Palmer GM, Anderson BJ (2011) The pharmacokinetics of intravenous paracetamol in neonates: size matters most. Arch Dis Child 96:575 - 580. doi:10.1136/adc.2010.204552
35. European Medicines Agency - EMEA-000898-PIP01-10 -Meropenem. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/ EMEA-000898-PIP01-10/pip-000668.jsp&mid=WC0b01ac058001d129&source= homeMedSearch. Accessed 11 Oct 2013
36. Fortinguerra F, Maschi S, Clavenna A, Bonati M (2010) Pain management in the paediatric population: the regulatory situation in Europe. Arch Dis Child 95:749 -753. doi:10.1136/adc.2009.179549